Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.

Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.

Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.

Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.

Bendamustine, often combined with other drugs, is effective and less toxic for certain blood cancers, but less effective for young, fit patients with CLL.

Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.

SADBE treatment led to complete hair regrowth in mice with alopecia areata by altering immune cell movement.

Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.

Twice-weekly 5 mg betamethasone helps hair regrowth in alopecia areata.

CD80CD86 deficiency causes hair loss by disrupting regulatory T cells.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

Etanercept, a psoriasis treatment, caused hair loss in a patient.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.

Machine learning can predict how well patients with alopecia areata will respond to certain treatments.

Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.

Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

Blocking certain proteins can significantly regrow hair in severe alopecia areata.

Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.

An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.

Spironolactone may help enlarge a small breast linked to Becker's nevus.